May 24, 2022
NHIA sent a letter to HHS requesting that the agency make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs). HHS’s vaccine program created coverage for home and suite-based infusions of COVID mABs, which is set to expire at the end of the year in which the public health emergency (PHE) is terminated. NHIA points out that access to home infusion for mABs for the treatment and prevention of hospitalization and death due to severe COVID-19 and is critical to maintaining preparedness for potential future variants. With no oral therapies approved for prophylaxis, mABs are the only source of preventive therapy for vulnerable patients who do not respond to vaccines, such as transplant patients, cancer patients, and the immunocompromised.
Last week concluded the 2024 National Home Infusion Association Annual Conference (NHIA 2024), which brings together more than 1,600 home and alternate site infusion professionals for four days of networking, education, and exhibits.
The National Home Infusion Association has announced the finalists for its 2024 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
CMS released its annual monitoring report[link] on the Medicare Part B Home Infusion Therapy (HIT) Services benefit showing that both provider participation and beneficiary utilization have declined over the past year.
